Skip to main
SANA

Sana Biotechnology (SANA) Stock Forecast & Price Target

Sana Biotechnology (SANA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sana Biotechnology is positioned favorably with a growth rate in biologics usage of 32% from 2022 to 2023, indicating a robust demand for innovative therapies in both the US and EU5 markets. The company’s focus on engineered cell therapies, coupled with the anticipated increased accessibility and lower costs of candidates like SG299, suggests potential for greater market uptake, particularly in challenging therapeutic areas such as systemic lupus erythematosus (SLE) and lupus nephritis (LN). Furthermore, the reported 40% increase in biologics usage among patients initiating or switching treatments underscores the expanding acceptance and integration of biologics within clinical practice, further bolstering the outlook for Sana’s therapeutic pipeline.

Bears say

Sana Biotechnology Inc faces significant challenges regarding the efficacy and safety of its lead programs, raising concerns about their potential to advance through clinical development successfully. The association of certain conditions, such as lupus nephritis (LN) and Type 1 diabetes (T1D), with poor prognoses—including high rates of kidney failure and elevated morbidity—places additional pressure on the company’s ability to demonstrate effective treatment outcomes. These factors contribute to a negative outlook, as the potential for halted development due to safety signals or ineffectiveness could hinder the company's ability to capitalize on unmet treatment needs in their targeted therapeutic areas.

Sana Biotechnology (SANA) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sana Biotechnology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sana Biotechnology (SANA) Forecast

Analysts have given Sana Biotechnology (SANA) a Buy based on their latest research and market trends.

According to 8 analysts, Sana Biotechnology (SANA) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sana Biotechnology (SANA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.